Congressman Steve Cohen (D-TN) introduced legislation today that would remove marijuana entirely from the federal Controlled Substances Act, eliminate mandatory minimum sentences for drug offenses and fundamentally restructure how the federal government classifies and regulates controlled substances.
The Public Health and Research Reforms in Controlled Substances Act of 2026 would make extensive changes to the nation’s primary federal drug law, including transferring significant authority from the Drug Enforcement Administration (DEA) to the Department of Health and Human Services (HHS), expanding scientific research protections and establishing a new scheduling framework based on public health risks and therapeutic benefits.
One of the legislation’s most significant provisions would require the removal of marijuana and tetrahydrocannabinols (THC) from all federal controlled substance schedules, rather than simply moving marijuana to a less restrictive classification.
The removal would apply retroactively to past offenses, pending cases and convictions, including juvenile adjudications. The legislation also establishes a process allowing individuals serving sentences for offenses carrying reduced penalties under the bill to request resentencing.
Unlike the ongoing federal marijuana rescheduling process, which would move marijuana to Schedule III while maintaining federal controls, Cohen’s proposal would remove marijuana from the Controlled Substances Act altogether.
The legislation would preserve the Food and Drug Administration’s authority over marijuana products and direct the agency to hold at least three public meetings within one year to examine issues including product safety, manufacturing, quality standards, marketing, labeling and sales. Federal employee marijuana testing could also remain in place.
Beyond marijuana, the bill would replace the existing five-schedule system with a framework consisting of four numerical classifications based on misuse potential and public health risks, combined with five alphabetical classifications evaluating therapeutic value.
Under this approach, controlled substances could receive classifications such as 1A, 2C or 3B, allowing regulators to distinguish a drug’s potential harms from its recognized medical benefits.
The measure would also expand the current eight-factor scheduling analysis to 15 factors and establish an independent expert advisory committee consisting of 15 to 25 members. HHS would assume primary authority over scheduling decisions, while the DEA would retain responsibility for preventing diversion and enforcing federal controlled substance laws.
Approximately 30 substances, including fentanyl, morphine, methamphetamine, psilocybin and ibogaine, would receive priority evaluations within two years. Remaining controlled substances would undergo review within eight years. These substances would not automatically be removed from federal control.
For scientific research, the legislation would transfer researcher registration responsibilities to HHS, establish broader research registrations and streamline approval procedures. It would also strengthen provisions intended to facilitate research under the HALT Fentanyl Act.
The proposal would eliminate federal mandatory minimum sentences for drug offenses while preserving judicial authority to impose prison terms, including substantial penalties for serious trafficking offenses. The United States Sentencing Commission would be required to revise sentencing guidelines, with provisions allowing certain previously sentenced individuals to seek reductions.
“Most Americans believe the ‘war on drugs’ has been a failure at cross purposes with good public policy and aimed largely at minorities with draconian mandatory minimum sentences for minor offenses that most now believe aren’t really offenses at all”, Cohen said.
“This bill would set comprehensive policies on all aspects of drug regulation while also defining the purpose of federal involvement. A thoughtful review of national drug policy is long overdue.”
The legislation expands substantially on Cohen’s Controlled Substances Act Clarification in Sciences Act, introduced in June. According to his office, the new measure is his 500th sponsored piece of legislation since entering Congress and represents the most comprehensive proposed overhaul of the Controlled Substances Act since its enactment in 1970.
The proposal has received endorsements from the National Organization for the Reform of Marijuana Laws (NORML), Drug Policy Alliance, Students for Sensible Drug Policy and the Multidisciplinary Association for Psychedelic Studies.
“For more than half a century, America’s failed drug policies have been built on the shaky and unscientific foundation of the scheduling system defined in the Controlled Substances Act”, said NORML Political Director Morgan Fox.
Fox said the existing system has failed to accurately classify substances based on scientific evidence, pointing specifically to marijuana’s placement in Schedule I.
Cohen’s legislation comes as federal officials separately consider broader marijuana rescheduling following the federal government’s decision earlier this year to move certain medical marijuana products to Schedule III.
Related posts:

Federal Marijuana Legalization Supporter Mary Peltola Wins Alaska U.S. Senate Race, Defeats Republic...

Texas Senator Says Political Barriers to Marijuana Legalization Are Fading, Designed 2027 Bill to At...








